The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Official Title: A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Study ID: NCT04511845
Brief Summary: Phase I, open-label, multi-center study
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Arizona Oncology, Tucson, Arizona, United States
Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
Minnesota Oncology, Minneapolis, Minnesota, United States
Rhode Island Hospital, Providence, Rhode Island, United States
MD Anderson Cancer Center, Houston, Texas, United States
Texas Oncology, Tyler, Texas, United States
University of Virginia, Charlottesville, Virginia, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Kurume University Hospital, Kurume, Fukuoka, Japan
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center, Fukuoka, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Center, Osaka, , Japan
Name: Sponsor Chugai Pharmaceutical Co. Ltd
Affiliation: clinical-trials@chugai-pharm.co.jp
Role: STUDY_DIRECTOR